Liver cancer patients get targeted chemo after surgery to stop return

NCT ID NCT07337421

Recruiting now Disease control Sponsor: Northern Jiangsu People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a specific chemotherapy cocktail (mFOLFOX) directly into the liver artery after surgery can prevent liver cancer from coming back in patients at high risk. About 30 adults who had their liver cancer removed will receive up to two rounds of this infusion. Researchers will track how long patients stay cancer-free and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mFOLFOX (oxaliplatin, leucovorin calcium, and 5-fluorouracil) given directly into the liver artery
What this could lead to: If it works, this could offer a way to lower the chance of liver cancer coming back after surgery for patients at high risk.
What could go wrong: This is a small, early-phase trial with only 30 participants and no comparison group, so results may not apply widely. The chemotherapy can cause side effects like nerve damage, low blood counts, and digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Clinical Medical College of Yangzhou University
RECRUITING

Yangzhou, Jiangsu, 225001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.